ASTRON (OGSG 2401): A multicenter prospective trial of ferric carboxymaltose for patients with gastrointestinal cancer and iron deficiency anemia undergoing chemotherapy
2025
Tumor Response Predicts Survival Time of Ramucirumab Plus Irinotecan in Advanced Gastric Cancer: An Exploratory Analysis of the Phase III RINDBeRG Trial
Identification of Prognostic Factors and Construction of Prognostic Index for Later-line Treatment in Advanced Gastric Cancer: Sub-analysis from the Phase III RINDBeRG Trial
Prognostic Implications of Neutropenia in Advanced Gastric Cancer: An Exploratory Analysis of the RINDBeRG Trial
Predictive Value of Nivolumab-Free Interval in Ramucirumab Plus Irinotecan Therapy: An Exploratory Analysis of the RINDBeRG Trial
Randomized Phase III Trial of Ramucirumab Beyond Progression Plus Irinotecan in Patients With Ramucirumab-Refractory Advanced Gastric Cancer: RINDBeRG Trial
Phase II Trial of Capecitabine Plus Bevacizumab for Elderly Patients With Metastatic Colorectal Cancer: OGSG 1102
Phase I/II study of neoadjuvant chemoradiotherapy consisting of S-1 and cisplatin for patients with clinically resectable type 4 and large type 3 gastric cancer (OGSG1205)
胃癌術後補助化学療法時の栄養介入が予後に与える影響（OGSG1108試験の追加観察研究）